Pink Sheet is part of Pharma Intelligence UK Limited

This site is operated by Pharma Intelligence UK Limited, a company registered in England and Wales with company number 13787459 whose registered office is 5 Howick Place, London SW1P 1WG. The Pharma Intelligence group is owned by Caerus Topco S.à r.l. and all copyright resides with the group.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction

Gum Tech and P&G

This article was originally published in The Tan Sheet

Executive Summary

Procter & Gamble pays Phoenix-based Zicam manufacturer approximately $1.6 mil. under terms of an R&D deal established earlier this year, Gum Tech announces Dec. 1. Arrangement between Gum Tech and the marketer of Vicks, NyQuil, DayQuil and Crest will continue for an unspecified period. Gum Tech also is working with Swedish Match in developing nicotine replacement products (1"The Tan Sheet" July 10, In Brief)

You may also be interested in...



Gum Tech

Specialty gum manufacturer announces joint venture with Swedish company for international distribution of nicotine gum and other non-tobacco nicotine products. Swedish Match will own 51% of the newly created company in exchange for a capital contribution of $10 mil. Gum Tech will own 49% and contribute certain intellectual property rights. All R&D and manufacturing for the joint venture will take place at Gum Tech's Phoenix, Ariz. facilities. The new firm will have a four-member board, with two members from each partner. Products are expected to launch in 2001. Stockholm-based Swedish Match sells smokeless tobacco, cigars and pipe tobacco

Supplement GMP Warning Letters Make Modest Debut In 2010

Finalization of a settlement between the Federal Trade Commission and Rexall Sundown regarding unsupported cellulite treatment claims for the firm's Cellasene dietary supplement hinges upon approval of two related class action settlements pending in California and Florida, according to FTC

In Brief

Combe sells most of its OTC brands

Topics

Latest Headlines
See All
UsernamePublicRestriction

Register

PS091954

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel